Amgen completes trial of romosozumab

Amgen has today (January 3rd) published the results of a 12-month study into the efficacy of romosozumab, a drug designed to treat low bone mineral density (BMD) in postmenopausal women. 

The trial, completed in conjunction with UCB, discovered that those receiving the treatment demonstrated significantly increased BMD at the femoral neck, total hip and lumbar spine when compared to those taking a placebo. Moreover, noticeable improvements were recorded at the three month stage.

According to the results – published in the New England Journal of Medicine – the BMD levels at the lumbar spine and hip were much higher than those observed using the currently-available FOSAMAZ and FORTEOTM/FORSTEO treatments.

Romosozumab is an investigational drug in phase III clinical development trial and  has not yet been approved by a regulatory authority. 

Michael McClung, director of the Oregon Osteoporosis Centre and lead study investigator, said: "The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment in women with postmenopausal osteoporosis."